AMX0035
Phase 2/3Completed 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Amyotrophic Lateral Sclerosis
Conditions
Amyotrophic Lateral Sclerosis
Trial Timeline
Nov 22, 2020 → Jan 31, 2023
NCT ID
NCT04516096About AMX0035
AMX0035 is a phase 2/3 stage product being developed by Amylyx Pharmaceuticals for Amyotrophic Lateral Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04516096. Target conditions include Amyotrophic Lateral Sclerosis.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05286372 | Pre-clinical | Completed |
| NCT06122662 | Phase 2/3 | Active |
| NCT05676034 | Phase 2 | Active |
| NCT05619783 | Phase 3 | Completed |
| NCT05021536 | Phase 3 | Active |
| NCT04987671 | Phase 1/2 | UNKNOWN |
| NCT04516096 | Phase 2/3 | Completed |
| NCT03488524 | Phase 2 | Completed |
| NCT03127514 | Phase 2 | Completed |
Competing Products
20 competing products in Amyotrophic Lateral Sclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo | Alector | Phase 2 | 44 |
| 89Zr-DFO-AP-101 | Eli Lilly | Phase 1 | 33 |
| Reldesemtiv + Placebo | Astellas Pharma | Phase 2 | 52 |
| Perampanel + Placebo Oral Tablet | Eisai | Pre-clinical | 23 |
| E0302 (mecobalamin) | Eisai | Phase 2/3 | 65 |
| E0302 (mecobalamin) + E0302 (mecobalamin) + Placebo | Eisai | Phase 2/3 | 65 |
| methylcobalamin + saline solution | Eisai | Phase 3 | 77 |
| ONO-2506PO | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-2506PO + ONO-2506PO | Ono Pharmaceutical | Phase 2 | 52 |
| ZYIL1 capsules 25 mg and 50 mg Placebo + ZYIL1 capsules 50 mg and 25 mg Placebo + ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg + Matching placebo 25 mg and Matching placebo 50 mg | Zydus Lifesciences | Phase 2 | 52 |
| LY4256984 + Placebo | Eli Lilly | Phase 1 | 33 |
| TCH346 | Novartis | Phase 2 | 52 |
| VHB937 | Novartis | Phase 2 | 52 |
| TCH346 | Novartis | Phase 2 | 52 |
| TCH346 | Novartis | Phase 2 | 52 |
| BLZ945 | Novartis | Phase 2 | 52 |
| TRO19622 | Roche | Phase 2/3 | 65 |
| Olesoxime + Placebo Comparator + Riluzole | Roche | Phase 3 | 77 |
| Bosutinib (Phase 1 part) + Bosutinib (Phase 2 part) | Pfizer | Phase 1/2 | 40 |
| Celecoxib + Creatine + Minocycline | Pfizer | Phase 2 | 51 |